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Background: Cholangiocarcinoma (CCA), a devastating neoplasm, is highly resistant to current chemotherapies.
CCA cells frequently overexpress the antiapoptotic protein myeloid cell leukemia-1(Mcl-1), which is responsible for
its extraordinary ability to evade cell death. Triptolide, a bioactive ingredient extracted from Chinese medicinal plant,
has been shown to inhibit cell proliferation and induce apoptosis in several cancers.
Methods: CCK-8 assay was performed to detect cell survival rate in vitro. DAPI staining and Flow cytometry
were used to analyze apoptosis. Western blot was performed to determine the expression levels of caspase-3,
caspase-7, caspase-9, PARP, and Mcl-1. Quantitative real-time PCR and immunofluorescence were used to detect
the expression levels of Mcl-1. The nude mice xenograft model was used to evaluate the antitumor effect of
triptolide in vivo.
Results: Triptolide reduced cell viability in cholangiocarcinoma cell lines in a dose- and time-dependent manner,
with IC50 values of 12.6 ± 0.6 nM, 20.5 ± 4.2 nM, and 18.5 ± 0.7 nM at 48 h for HuCCT1, QBC939, and FRH0201
respectively. Triptolide induced apoptosis in CCA cell lines in part through mitochondrial pathway. Using
quantitative real-time PCR, western blot and immunofluorescence, we have shown that triptolide downregulates
Mcl-1 mRNA and protein levels. Furthermore, triptolide inhibited the CCA growth in vivo.
Conclusions: Triptolide has profound antitumor effect on CCA, probably by inducing apoptosis through inhibition
of Mcl-1. Triptolide would be a promising therapeutic agent for CCA.
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Cholangiocarcinoma (CCA) is a highly malignant adeno-
carcinoma arising from the bile duct epithelial cells. The
overall incidence and mortality rates of this fatal neoplasm
appear to be increasing in several western countries [1-5].
CCA is characterized by a poor prognosis and overall low
survival rates [6]. Surgical resection and liver transplant-
ation are considered the only two potentially curative ther-
apies. Unfortunately, majority of patients have advanced
disease at the time of diagnosis and miss the optimal time
for these curative treatment options. Currently available* Correspondence: 13770755008@126.com; zouxiaoping795@hotmail.com
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unless otherwise stated.chemotherapic agents and conventional radiotherapy are
not effective in prolonging long-term survival of CCA pa-
tients. Therefore, it is necessary to develop novel effective
therapeutic strategies against this neoplasm.
Natural products have played a significant role over
the years in the development of anticancer drugs. Trip-
tolide is a principal bioactive ingredient of the Chinese
herb Tripterygium wilfordii Hook F, which has been used
in traditional Chinese medicine for treating autoimmune
and inflammatory diseases for centuries [7]. In addition to
its immunosuppressive and anti-inflammatory properties,
triptolide has attracted extensive research interest in its
antitumor effects. Previous studies have shown that tripto-
lide is highly effective against a variety of cancer types, in-
cluding melanoma, breast cancer, bladder cancer, andd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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pact on CCA.
The aim of this study was to investigate the efficacy
and possible mechanism of triptolide against human
CCA both in vitro and in a nude mice xenograft model.
We found that triptolide inhibited cell survival at low
nanomolar concentrations. The mechanism by which trip-
tolide induced CCA cell death was probably by inducing
apoptosis through inhibition of myeloid cell leukemia-1
(Mcl-1). In vivo assay also verified the anticancer effect of
triptolide in this neoplasm. Our findings provide the ex-




Triptolide and 4′, 6-diamidino-2-phenylindole (DAPI)
were purchased from Sigma (St. Louis, MO, USA). Alexa
Fluor 488 (green) conjugated goat anti-rabbit secondary
antibody and TRIzol were purchased from Invitrogen
(Carlsbad, CA, USA). Cell counting kit-8 (CCK-8) was
provided by Dojindo Laboratories (Kumamoto, Japan).
Annexin V Apoptosis Detection kit FITC was purchased
from eBioscience (San Diego, CA, USA). PrimeScript™
RT Master Mix and SYBR Premix Ex Taq reagents were
purchased from Takara Biotechnology (Dalian, China).
Caspase-3 activity assay kit was obtained from Beyotime
Institute of Biotechnology (Hangzhou, China). Antibodies
against caspase-3 (9662), caspase-7 (9492), caspase-9
(9502), PARP (9532), Mcl-1(5453), and actin (4967)
were from Cell Signal Technology (Boston, MA, USA).
Antibody against Mcl-1(sc-819) was from Santa Cruz
Biotechnology (San Jose, CA, USA). HRP-linked anti-
rabbit secondary antibody was from Cell Signal Technol-
ogy. Antibody against Ki67 (Kit-0005-2) was obtained
from Maixin Bio (Fuzhou, China).
Cell culture
The intrahepatic CCA cell line HuCCT1 was obtained
from Jiangsu Province Hospital (Nanjing, China). The
extrahepatic CCA cell line QBC939 was a generous gift
from Dr. Qiang Huang (Anhui Provincial Hospital, Hefei,
China). The extrahepatic CCA cell line FRH0201 was ob-
tained from Qilu Hospital of Shandong University (Jinan,
China). QBC939 and FRH0201 were cultured in RPMI-
1640 medium supplemented with 10% FBS. HuCCT1
was cultured in DMEM containing 10% FBS. All cells
were maintained in a humidified incubator at 37°C with
5% CO2.
Cell viability assay
Cell viability was detected by CCK-8 assay. Cells were
seeded into 96-well plates at 3 × 103 cells per well and cul-
tured overnight at 37°C. After treatment with triptolide atindicated concentrations for 24 and 48 h, 10 uL of the
tetrazolium substrate was added to each well of the plate.
Plates were incubated at 37°C for 1 h, after which the ab-
sorbance at 450 nm was measured. All experiments were
done in triplicate and repeated three independent times.
DAPI staining for apoptosis assessment
Cells were seeded into 6-well plates and cultured as de-
scribed above. After indicated treatments, the cells were
stained with 10 μg/mL DAPI for 15 min. Morphologic
changes in apoptotic nuclei were observed and photo-
graphed under the fluorescence microscope. Apoptosis
was defined as the presence of nuclear condensation or
fragmentation on DAPI staining.
Caspase-3 activity assay
Caspase-3 activity was detected using a caspase-3 assay
kit from Beyotime. Briefly, CCA cells were exposed to
different concentrations of triptolide for 12 h. The cells
were washed twice with PBS, and lysed for 15 min on ice.
Lysates were centrifuged at 10,000 g for 15 min at 4°C.
For each well in a 96-well microplate, cell lysate (10 μl),
assay buffer (80 μl), and caspase-3 substrate (Ac-DEVD-
pNA, 10 μl) were combined. The samples were incubated
at 37°C for 12 h and their absorbance was recorded at
405 nm using a microplate reader (BioTek, USA).
Annexin V-FITC apoptosis assay
Apoptosis induction by triptolide was assessed by flow cy-
tometry using Annexin V-FITC labeling. About 2 × 105
cells/well were seeded in a 6-well plate and treated with
different concentrations of triptolide for 24 h. Apoptosis
was determined using Annexin V-FITC Apoptosis Detec-
tion kit and performed according to the instructions. Data
were analyzed using FlowJo Version 8.7.
Quantitative real-time PCR
Total RNA was extracted from cultured cells using TRI-
zol reagent and cDNA was synthesized using Prime-
Script™ RT Master Mix according to the manufacturer’s
instructions. Quantitative real-time PCR experiments
were done with the 7500 Real-time PCR System (Ap-
plied Biosystems) using SYBR Premix Ex Taq reagents.
The primers for quantifying Mcl-1 are 5′-CATTTCT
TTTGGTGCCTTTGTG-3′ and 5′-CCAGTCCCGTTT
TGTCCTTAC-3′. The primers for quantifying β-actin
are 5′-GGGCACGAAGGCTCATCATT-3′ and 5′-AG
CGAGCATCCCCCAAAGTT-3′. All data were normal-
ized to the human β-actin. All experiments were done in
triplicate and repeated three independent times.
Western blot
Cells were lysed in RIPA buffer (50 mM Tris–HCl with
pH 7.4, 150 mM NaCl, 0.25% deoxycholic acid, 1% NP-
Figure 1 Triptolide inhibited cell survival of CCA cells. (A-C)
HuCCT1 (A), QBC939 (B), and FRH0201 (C) cells were incubated with
triptolide (0–200 nM) for 24 and 48 h. Cell viability was evaluated by
CCK-8 assay.
Table 1 IC50 for cholangiocarcinoma cell lines treated
with triptolide
Cell lines IC50 at 24 h (nM) IC50 at 48 h (nM)
HuCCT1 124.1 ± 21.5 12.6 ± 0.6
QBC939 82.2 ± 5.1 20.5 ± 4.2
FRH0201 54.1 ± 13.1 18.5 ± 0.7
Cells were plated in 96-well plates and treated with indicated concentrations
(0-200 nM) of triptolide for 24 and 48 h. IC50 values were calculated using a
nonlinear dose–response curve fit and expressed as mean ± SEM.
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solved by 8–12% sodium dodecyl sulfate–polyacrylamide
gel electrophoresis and transferred to polyvinylidene
fluoride membranes. The membranes were blocked by
5% non-fat dry milk in Tris buffered saline containing
0.1% Tween-20 for 1 hour at room temperature. Thenthey were incubated with the desired primary antibodies
(1:1000 dilutions) overnight, followed by appropriate
HRP-conjugated secondary antibodies (1:2000 dilutions).
Antibody binding was detected using Millipore Immobi-
lon Western Chemiluminescent HRP Substrate accord-
ing to the manufacturer’s instructions.Immunofluorescence
Cells were cultured on 24-well plates, fixed with 4% para-
formaldehyde, and blocked for one hour with 5% normal
goat serum, followed by incubation with polyclonal anti-
bodies against Mcl-1 (1:50) overnight at 4°C. Cells were
then rinsed with PBS and incubated with Alexa Fluor 488-
conjugated goat anti-rabbit secondary antibody (1: 200).
Cells were counter-stained with DAPI (2 μg/ml) and ex-
amined by fluorescence microscopy.Xenograft in nude mice
The mouse experiments were conducted in the Animal
Laboratory Center of Nanjing Drum Tower Hospital
(Nanjing, China). Nude mice were purchased from the
Comparative Medicine Center of Yangzhou University
(Yangzhou, China). The animal experiments were approved
by the Institutional Animal Care and Use Committee of
Nanjing Drum Tower Hospital, Nanjing University Medical
School.
HuCCT1 cells (1 × 107cells) were suspended in 100 μl
serum free medium and injected subcutaneously into
the left flank of 4- to 6-week old male BALB/c nu/nu
nude mice. Tumor size was measured with digital caliper
and calculated as V = LS2/2 (where L is the longest diam-
eter and S is the shortest diameter). After 7 days when the
tumor size reached about 150 mm3, mice were randomly
segregated into two groups with five mice in each group.
Mice were treated daily by intraperitoneal injection of
triptolide at a dose of 0.2 mg/kg body weight or vehicle
control. Tumor volume and animal weight were measured
every three days and at the end of about 3 weeks after
treatment, mice were sacrificed. Tumors were excised,
weighted, fixed in 10% neutral formalin, and embedded in
paraffin for subsequent histological analysis.
Figure 2 Triptolide induced apoptosis of CCA cells. (A) DAPI staining (original magnification, ×200) was used to determine the apoptosis.
Arrows indicate cells with nuclear condensation and fragmentation. (B-D) HuCCT1 (B), QBC939 (C), and FRH0201 (D) cells were incubated with
triptolide (0-100 nM) for 24 h and Annexin V levels were assessed by flow cytometry. *p < 0.05, ***p < 0.001, compared with control.
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Paraffin embedded sections were deparaffinized and
rehydrated in graded alcohols and xylene using standard
procedures, and either stained with H & E for histology,
or Ki67 as a measure of cell proliferation. For Ki67 im-
munohistochemistry, sections were incubated with pri-
mary antibodies overnight at 4°C followed by secondary
antibody for 1 h at room temperature. Slides were devel-
oped by DAB reagent and counter stained with heam-
toxylin for 30 s.Statistical analysis
All the statistical analyses were performed using Prism
5.0 (Graphpad Software Inc., San Diego, USA). Data are
expressed as the mean ± SEM of three independent ex-
periments at least. The Student’s t test was used to
compare the control and treated groups. In experiments
involving more than three groups, one-way ANOVA and
Bonferroni’s post hoc test were used. All statistically tests
were two sided. Differences were considered statistically
significant when the P value was less than 0.05.Results
The effect of triptolide on CCA cell viability
We evaluated the effect of triptolide on three CCA cell
lines: HuCCT1, QBC939, and FRH0201. Cell viability was
assessed by CCK-8 assay after incubation in mediumFigure 3 Triptolide induced caspase activation in CCA cells. (A-C) Casp
concentrations of triptolide for 12 h. Data are presented as fold increases a
caspase-7 were analyzed by western blot after treatment with triptolide (10
western blot after treatment with triptolide (100 nM) for 24 h. *p < 0.05, **pcontaining triptolide at concentrations of 0 to 200 nM for
24 and 48 h. All the cell lines tested showed a significant
dose- and time-dependent decrease in cell viability after
triptolide treatment (Figure 1). The levels of cytotoxicity
were indicated as the concentration that inhibits the cell
survival by 50%, IC50. As shown in Table 1, triptolide had
an extremely low IC50 of nanomolar level on CCA cells.
The IC50 values of triptolide on HuCCT1, QBC939, and
FRH0201 at 48 h were 12.6 ± 0.6 nM, 20.5 ± 4.2 nM, and
18.5 ± 0.7 nM respectively.Triptolide induces apoptosis in CCA cells
To elucidate the mechanism by which triptolide causes cell
death in CCA cells, we used DAPI staining and Annexin
V-FITC assay to evaluate whether triptolide could induce
apoptosis in CCA cells. As shown in Figure 2A, nuclear
condensation and fragmentation on DAPI staining was
obvious in triptolide-treated cells. The induction of
apoptosis by triptolide was validated by increased staining
of Annexin V. Treatment of HuCCT1 cells with 50 nM to
100 nM triptolide for 24 h resulted in an approximately
3.2-fold to 4.7-fold increase in apoptosis (Figure 2B).
Likewise, treatment of QBC939 and FRH0201 cells with
triptolide shows a dose-dependent increase in Annexin
V staining (Figure 2C and D). Our data show that treat-
ment with triptolide induces apoptosis in all CCA cell
lines tested.ase-3 activity in CCA cells were analyzed after treatment with indicated
s compared with control cells. (D) Protein expression of caspase-3 and
0 nM) for 24 h. (E) Protein expression of caspase-9 was analyzed by
< 0.01, ***p < 0.001, compared with control.
Figure 4 Triptolide inhibited Mcl-1 mRNA expression in HuCCT1
and QBC939 cells. (A-B) Triptolide (25–100 nM) significantly
reduced Mcl-1 mRNA expression (as assessed by real-time PCR) in
both HuCCT1 (A) and QBC939 (B) cells. Expression of Mcl-1 was
normalized against the housekeeping gene β-actin. ***p < 0.001,
compared with control.
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in CCA cells
Caspase-9 is known to be downstream of cytochrome c
release from the mitochondria in the intrinsic apoptosis
pathway and is commonly used as a measure of intrinsic
apoptosis. As seen in Figure 3E, treatment with triptolide
decreased procaspase-9 and increased cleaved caspase-9
in both HuCCT1 and QBC939 cells. Activated caspase-9
activates caspase-3 and caspase-7, which in turn induces
PARP cleavage. As shown in Figure 3A-C, triptolide dose-
dependently increased caspase 3 activity as early as 12 h
after treatment. Triptolide treatment also reduced the
procaspase-3 and procaspase-7 in all three CCA cell lines
(Figure 3D). Our results suggest that triptolide induces
apoptosis, at least in part, through the intrinsic mitochon-
drial pathway.
The effect of triptolide on Mcl-1 levels in CCA cells
Our next step was to investigate the mechanism by
which triptolide induces apoptosis. CCA cells frequently
overexpress the antiapoptotic Bcl-2 family member Mcl-1,
which has been shown to play a critical role in cell survival
and apoptosis resistance of CCA [10]. Instead, other Bcl-2
family members like Bcl-2 or Bcl-xL play less important
roles in the apoptosis of CCA cells. We hypothesized that
triptolide induced apoptosis in CCA cells by inhibiting
Mcl-1, and then systematically tested our hypothesis. The
effect of triptolide on Mcl-1 expression was analyzed by
real-time PCR, western blot, and immunofluorescence.
Our results clearly show that triptolide with concentra-
tions of 25 nM to 100 nM significantly decreased Mcl-1
mRNA expression of HuCCT1 and QBC939 cells at both
6 and 12 h, as compared with control cells not exposed to
triptolide (Figure 4). In accordance with its effect on
mRNA expression, triptolide also significantly decreased
Mcl-1 protein levels in all CCA cells tested in a time- and
dose- dependent way (Figure 5A and B). The decrease of
Mcl-1 protein levels was also corresponded with an in-
crease of apoptosis as indicated by increase of cleaved-
PARP, suggesting that Mcl-1 downregulation may be a
primary mechanism for the proapoptosis property of
this drug. Mcl-1-inhibiting effects of triptolide were fur-
ther confirmed by immunofluorescence in HuCCT1
and QBC939 cells (Figure 5C). Taken together, these re-
sults show that triptolide causes CCA cell death via
downregulation of Mcl-1 expression.
The effect of triptolide on CCA tumor growth in vivo
The anticancer effect of triptolide was further analyzed
in a xenograft tumor model by transplanting HuCCT1
cells into nude mice. On the 7th day after implantation,
mice were randomly divided into 2 groups, with 5 tumor-
bearing mice in each group. Intraperitoneal injections of
triptolide (0.2 mg/kg/d) significantly inhibited the tumorgrowth for 22 days compared with the vehicle group
(Figure 6A). Tumor weight was also significantly re-
duced after triptolide treatment (Figure 6C). Ki67 is a
proliferation marker required for cell-cycle progression,
replication, and DNA repair. As shown in Figure 6E,
tumor cell proliferation, as indicated by Ki67, was re-
duced significantly by the treatment of triptolide. To as-
sess the toxicity of the treatment, we measured mouse
body weight every three 3 days and no significant weight
loss was observed in the mice treated with triptolide
compared with vehicle group during the whole treat-
ment period (Figure 6B).
Discussion
In this study, we explored the biological effects of a nat-
ural product, triptolide, on CCA cells. This drug induces
CCA cell death with low nanomolar IC50 values. The
mechanism by which triptolide induces CCA cell death is
through induction of apoptosis via the inhibition of Mcl-1.
Figure 5 Triptolide time- and dose-dependently inhibited Mcl-1 protein expression and induced PARP cleavage in CCA cells. (A) Cells
were treated with 100 nM triptolide for indicated times or (B) with indicated concentrations of triptolide for 12 h. Whole cell extracts were
prepared and analyzed using indicated antibodies. β-actin served as a loading control. (C) HuCCT1 and QBC939 cells were treated with 100 nM
triptolide for 24 h and then analyzed for the expression of Mcl-1 by immunofluorescence (original magnification, ×200).
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cantly decreased CCA cell viability in three CCA cell lines:
HuCCT1, QBC939, and FRH0201. Although the mechan-
ism of triptolide against tumor cells has not been fully
understood, it has been shown to induce apoptosis in
some cancer cells [11-13]. Then we examined whether
triptolide induced CCA cell death through the apoptosis
pathway. Triptolide dose-dependently induced apoptosis
in all CCA cell lines tested, with significant increases in
Annexin V staining and nuclear condensation and frag-
mentation. Caspase activation is the key event of apop-
tosis. One pathway of caspase activation is the intrinsic
mitochondrial pathway, from which cytochrome c translo-
cates into the cytosol, which then interacts with apoptosisprotease activator factor-1 and activates caspase-9. Acti-
vated caspase-9 then activates downstream caspase-3 and/
or caspase-7, which in turn induces PARP cleavage. Our
results show that, following incubation with triptolide,
caspase-9 is activated, accompanied by significant increase
in caspase-3 activity and PARP cleavage, thus strongly
suggesting that triptolide induced cell death through the
mitochondrial apoptotic pathway. These results concur
with those reported in pancreatic cancer cell lines and
leukemic cell lines treated with triptolide [12,13].
The Bcl-2 protein family comprises major regulators of
cell survival which can promote or suppress apoptosis [14].
Mcl-1 is an antiapoptotic member of Bcl-2 protein family,
which can promote cell survival through suppression of




























































































Figure 6 Triptolide inhibited CCA cell growth in vivo. HuCCT1 cells were injected subcutaneously into the left flanks of athymic nude mice.
When tumors reached a size of approximately 150 mm3, mice were i.p. with triptolide (0.2 mg/kg) or vehicle control every day for a total of
22 days. (A) Tumor volume was measured every three days using calipers and calculated as described in Materials and Methods (n = 5). (B) The
mouse weight was measured every three days to monitor the drug effects. (C) At the end of the study, the excised tumors from each group
were weighed. (D) Resected tumors from each group were photographed. (E) H & E and Ki67 staining in the tumor tissues of triptolide and
vehicle treated mice (original magnification, ×200). Arrows show the Ki67 expression in tumor tissue. *p < 0.05, **p < 0.01, compared with control.
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lated evidence indicates that Mcl-1 is essential for develop-
ment and survival of acute myelogenous leukemia and
various solid tumors including CCA [16,17]. Mcl-1 medi-
ates the resistance to apoptosis by blocking the mitochon-
dria pathway [18]. Mcl-1 is frequently overexpressed in
CCA cells and human CCA tissues [10,19,20]. The elevated
expression of this protein plays a pivotal role in protecting
the CCA cells from apoptosis and promoting CCA cell sur-
vival [10,19,21]. Instead, other Bcl-2 family members like
Bcl-2 and Bcl-xL has less important antiapoptotic effects in
CCA [10]. The implication of these reports is that inhibit-
ing Mcl-1 expression, using genetic or pharmacological
approaches, could be a potentially effective strategy against
this neoplasm. However, only a small number of pharma-
cologic Mcl-1 inhibitors have been identified [16]. Our
study has shown that low concentrations of triptolide can
inhibit both mRNA and protein expression of Mcl-1 as
early as 6 h after the treatment and induce potent apop-
tosis through mitochondria pathway. To the best of our
knowledge, this is the first report demonstrating Mcl-1 as a
target of triptolide in CCA cells. However, how triptolidedownregulates Mcl-1 transcription is not clear and needs
further exploration.
We also examined the effect of triptolide on CCA
growth using a nude mice model of CCA derived from
the highly malignant CCA cell line HuCCT1. Daily in-
traperitoneal injection of 0.2 mg/kg triptolide substan-
tially suppressed the growth of established CCA tumors,
indicating the tumor regression potential of triptolide.
Importantly, no toxicity was observed at the dose of
0.2 mg/kg per day. We show here for the first time that
triptolide inhibits CCA growth in a nude mice xenograft
model. Although triptolide is an effective antitumor com-
pound in vitro, its use in vivo has been restricted owing to
its low solubility in water. Recently, a water-soluble analog
of triptolide, Minnelide, designed and synthesized by the
University of Minnesota, has overcome this issue and
shown considerable efficacy in preclinical studies against
pancreatic cancer, osteosarcoma, and lung carcinoma
[22-24]. In addition, Minnelide has shown to be more ef-
fective than gemcitabine in the preclinical study against
pancreatic cancer. Minnelide is now undergoing Phase I
clinical trial against the advanced gastrointestinal tumors
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cancer. Resistance to apoptosis is a key factor preventing
response to conventional therapy in cancer. Triptolide
has been shown to cooperate with several conventional
chemotherapeutic drugs to induce apoptosis in different
cancer cell lines and increase the sensitivity to various
chemotherapeutic agents [25-29]. Whether triptolide
can sensitize the CCA to conventional chemotherapy
has not been investigated and requires further exploration
because CCA is highly resistant to current chemothera-
peutic agents. The cytokine tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) is an attractive agent
for the treatment of advanced cancers including CCA,
through selective induction of cancer cell apoptosis. Prior
work [30,31] has shown that triptolide may sensitize CCA
cells to TRAIL via apoptosis. Taniai et al. [10] has de-
scribed that many cholangiocarcinoma cells are resistant
to TRAIL-mediated apoptosis through overexpression of
Mcl-1. Our result shows that triptolide decreases Mcl-1
expression, suggesting that triptolide sensitizes cholan-
giocarcinoma cells to TRAIL partially through Mcl-1
inhibition. This combination therapy with triptolide and
TRAIL has important therapeutic potential in clinical
translation for cholangiocarcinoma.
Conclusions
In summary, our study provides evidence that triptolide
inhibits the tumor growth in CCA both in vitro and
in vivo. The main mechanism of this effect might be in-
ducing intrinsic apoptosis via inhibition of Mcl-1. These
findings suggest that triptolide is a promising therapeutic
agent for CCA.
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